Lurbinectedin (ZEPZELCA®) in combination with atezolizumab for extensive-stage small cell lung cancer.

AIHTA Appraisal Board Author Group, HTA Austria (2026): Lurbinectedin (ZEPZELCA®) in combination with atezolizumab for extensive-stage small cell lung cancer.. Decision Support Document for the Austrian Appraisal Board 009.

[thumbnail of Appraisal_Board_Document_009.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
4MB
[thumbnail of Appendix]
Preview
PDF (Appendix) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
6MB
Abstract

Lurbinectedin (ZEPZELCA®), in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. It is a novel alkylating antineoplastic agent that acts as a selective inhibitor of oncogenic transcription, leading to apoptosis of tumour cells. It is administered as an intravenous infusion of 3.2 mg/m² body surface area over 60 minutes every 21 days until disease progression or unacceptable toxicity. It received marketing authorisation from the European Commission in May 2026 and maintained its orphan designation.

The clinical assessment was based on the Joint Clinical Assessment (JCA) conducted under Regulation (EU) 2021/2282. Efficacy and safety rest on a single open-label randomised controlled phase III trial, IMforte, in which 483 patients without progression after four induction cycles were randomised to lurbinectedin plus atezolizumab (n=242) or atezolizumab monotherapy (n=241). At the latest data cut-off (12th February 2025), investigator-assessed progression-free survival was statistically significantly improved with lurbinectedin plus atezolizumab compared with atezolizumab monotherapy (hazard ratio (HR) 0.56 [95% CI 0.46; 0.69]; p<0.0001). The prespecified significance boundary for overall survival was crossed at the interim 2024 cut-off (HR 0.73; 95% CI 0.57–0.95), but at the 2025 cut-off, the difference was no longer statistically significant (HR 0.81; 95% CI 0.65–1.01; median 13.9 vs 11.1 months). No statistically significant differences were observed in objective response rate, complete response rate or duration of response, and no consistent improvement in health-related quality of life was demonstrated, with time to deterioration in physical functioning, role functioning and nausea/vomiting being even shorter with lurbinectedin. Adverse events, grade ≥3 events (notably haematological toxicities), serious events, treatment discontinuations and fatal events (5.0% vs 2.5%) were more frequent with lurbinectedin. Interpretation is limited by the open-label design and by differing treatment and observation durations between arms.

No Austrian pharmacoeconomic model or budget impact analysis was submitted. Two published cost-utility analyses from China and the United States concluded that lurbinectedin plus atezolizumab was not cost-effective compared to atezolizumab monotherapy, with reported ICERs of approximately €340,000 per QALY and €703,000–975,000 per QALY, respectively. At Austrian list prices and median treatment durations adopted from the IMforte trial, direct medical costs amount to €106,778 per patient, compared with €22,196 for atezolizumab monotherapy. Assuming 180–250 eligible patients annually, the cumulative three-year net budget impact is estimated at €31.2–43.3 million, decreasing to €14.3–19.9 million if equal treatment duration is assumed.

Although no substantial organisational changes are anticipated due to the integration of lurbinectedin into Austrian clinical practice, recommendations include adjusting treatment protocols, increasing interdisciplinary coordination, neutropenia prophylaxis, careful adverse event management, and staff training. The value of lurbinectedin will depend on the maturity of the survival data, price negotiations and its future positioning within an evolving treatment landscape.

Item Type:DSD: Appraisal Board
Keywords:Lurbinectedin, small-cell lung cancer, maintenance treatment, antineoplastic agent, selective inhibitor of oncogenic transcription process
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
W Health professions > W 74-80 Medical economics. Health care costs
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Related URLs:
Language:English
Series Name:Decision Support Document for the Austrian Appraisal Board 009
Deposited on:19 Nov 2026 11:09
Last Modified:19 Nov 2026 12:13

Repository Staff Only: item control page